semaglutide and health conditions Comparative safety side effects of and tirzepatide: Implications for clinical decision-making in obesity management Transform With Semaglutide: Weight Loss

Discover research-focused product information, peptide science resources, and related research compounds from a trusted supplier.

However, gastrointestinal side effects related to GLP-1 RA need appropriate clinical management to mitigate risks and maximize the benefits of therapy in people with IBD

Semaglutide nausea affects up to 40% of patients during treatment initiation

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity

What role do you see oral GLP-1s playing in formulary strategy